OptimizeRx vs. GoodRx: Which Digital Health Stock is the Better Buy?

The article favors OptimizeRx over GoodRx, citing OPRX’s AI-enabled DAAP adoption, improved conversion of pilot programs into scaled deployments, and upwardly revised 2026 adjusted EBITDA guidance of $21-$25 million. By contrast, GoodRx faces softer prescription transaction revenue, margin pressure, and 2026 guidance for revenue of $750-$780 million and adjusted EBITDA of at least $230 million, both below 2025 levels. OPRX also has a better Zacks Rank (#1 vs. #4) and a lower price/book valuation (0.94x vs. 1.28x), though both stocks have fallen over the past year.

Analysis

OPRX looks like the cleaner second-order beneficiary of the current AI/healthcare workflow trade because its AI layer is tied to budget reallocation inside pharma, not just incremental usage. If customers are using generative AI to cut content costs, the likely next step is not lower spend overall but a shift toward precision activation, which should favor platforms that can prove measurable lift at the point of care. That makes OPRX more of a “share of wallet” winner than a pure growth story, and it also reduces the probability that AI becomes a direct disintermediator in the near term.

The near-term issue for OPRX is not product-market fit but buying behavior: short contract durations and paused campaigns create timing risk that can distort the P&L for 1-2 quarters. That setup usually matters more for smaller-cap names because a modest miss can force multiple compression before the underlying demand recovers. The key tell is whether management’s back-half weighting actually turns into sequential bookings acceleration by midyear; if not, the market will keep discounting the margin story as “good unit economics, weak visibility.”

GDRX is in a tougher position because its model is more exposed to pricing and partner economics than to a clean product adoption curve. The second-order issue is that even stable consumer engagement does not protect EBITDA if pharmacy and PBM negotiations keep squeezing monetization per transaction; in that case, top-line can look resilient while contribution margin quietly erodes. That creates a mismatch between perceived defensiveness and actual earnings sensitivity, which is why estimate revisions are likely to stay negative until contractual reset points clear.

Contrarian takeaway: the market may be underestimating how much operating leverage exists in OPRX if sales cycles re-open, while overestimating the durability of GDRX’s scale advantages under continued margin pressure. On a 6-12 month horizon, OPRX is the better asymmetric setup; GDRX may look statistically cheap after the drawdown, but it lacks a clear catalyst for multiple repair unless pricing trends stabilize and management proves it can grow EBITDA without further mix dilution.

Key Decisions for Investors

• Go long OPRX on a 3-6 month horizon, preferably on any post-guidance pullback; risk/reward is attractive if bookings re-accelerate because estimate upside can drive a re-rating from a depressed base.
• Short GDRX or avoid adding until there is evidence that transaction pricing and partner economics have stabilized; the setup favors continued estimate downgrades over near-term multiple expansion.
• Pair trade: long OPRX / short GDRX for relative value over 3-9 months; thesis is that one has a catalyst for margin-supported growth while the other faces structural monetization pressure.
• For more conservative exposure, buy OPRX call spreads 4-6 months out to capture upside from a second-half recovery while limiting downside if the spending pause persists.
• Use any GDRX bounce on better-than-feared user metrics to reduce risk; without clearer guidance inflection, rallies are likely to be sold as the market focuses on EBITDA compression.